Navigation Links
Papua New Guinea declares first national conservation area
Date:3/2/2009

Port Moresby, Papua New Guinea The southeast Pacific nation of Papua New Guinea, home to some of the most biologically diverse ecosystems on Earth, has created its first national conservation area to preserve forever a swath of pristine tropical forest larger than Singapore.

The decision by the Papua New Guinea (PNG) government, in concert with local communities neighboring the newly established YUS Conservation Area, results from more than a decade of work with conservation biologists from Woodland Park Zoo in Seattle and Arlington, Va.-based Conservation International (CI).

Named for its three main rivers the Yopno, Uruwa and Som of the Huon Peninsula the YUS Conservation Area covers 187,800 acres (76,000 hectares or 760 square kilometers) of tropical forest stretching from PNG's northern coast to interior mountains.

A hallmark of modern conservation, the new protected area offers multiple benefits for both wildlife and people. The tropical forest stores huge amounts of carbon, so protecting it prevents the release of harmful greenhouse gas emissions that cause climate change. The lush forest ecosystem teems with life and provides countless resources and services that sustain the 10,000 villagers living in the surrounding YUS ecosystem. In addition, the forest is critical habitat for Matschie's tree kangaroos, a species listed as Endangered by the IUCN and one of Earth's more unique creatures with a bear-like head, bushy tail and marsupial's pouch.

"By creating the country's first national conservation area, the PNG government and people have established a much-needed safe zone for the irreplaceable biodiversity it contains," said Dr. Lisa Dabek, field conservation director at Woodland Park Zoo and director of the zoo's Tree Kangaroo Conservation Program. "Just as important, the protected area will contribute to long-term efforts to address the climate change threat by preserving critical forest habitat."

Wood
'/>"/>

Contact: Tom Cohen
tcohen@conservation.org
703-341-2729
Conservation International
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Marathon and Partners Announce $28 Million, 5-Year Extension of Life Saving Malaria Control Project in Equatorial Guinea
2. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
3. Landauer, Inc. Declares Regular Cash Dividend
4. On the Heels of Court Ruling Denying Autism-Vaccine Link, U.S. Federal Court Declares MMR Vaccine Caused Autism in a Young Boy
5. Video: On 100th Anniversary, Mental Health America Declares Its Time for Mental Health
6. Federal Court Declares Vaccines Do Not Cause Autism
7. Service Corporation International Declares Quarterly Cash Dividend
8. Mesa Labs Declares Quarterly Dividend
9. NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
10. Hawkins, Inc. Declares Semi-Annual Cash Dividend of $0.26 Per Share
11. Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... ONDAMED® praised by Suzanne Somers in her N.Y... Cornwall, NY (PRWEB) December 2, 2009 --... Who Are Curing Cancer, And How to Prevent Getting...doctors who are successfully using the most innova...he body rather than tear it down. This is a subjec...
(Date:12/2/2009)... Leading medical device software engineering consu... 13485 certification. A relatively few medical dev...ually achieved ISO 13485 certification. Many medic...adhere to other ISO standards as well. However, it...gineering consulting firm to achieve the rigorous ...
(Date:12/2/2009)... 2 Targeted breast ultr...g lumps, is a safe, reliable and cost-effective al... 40, according to the findings of two studies pres...cal Society of North America (RSNA). ,, "By per...uce the number of expensive and avoidable invasive...
(Date:12/2/2009)...arge-scale clinical trial presented today at the a... America (RSNA) provide the first strong evidence ...women with dense breasts who are at elevated risk ...d that MRI is highly sensitive in depicting early ... with ultrasound in addition to mammography signif...
(Date:12/1/2009)...K, Dec. 1 Reportlinker.com announc...in its catalogue: ,, Emerging Clinical Trial ...g healthcare and regulatory environment ,, h...cal-Trial-Locations---India-Market-dynamics-and-th...tml ,, Over the last decade pharmaceutical and...
Breaking Medicine News(10 mins):Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 2Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 7
...ovember issue of Developmental Psychology has expl...picture-book reading with their children, // which...them to the world outside. This is thought to be h... and spend approximately 40 minutes a day reading ...
...la will soon head for the Maldives to care for pat...s from Kerala are to leave for the Maldives courte... Promotion Consultants (ODEPC). 'The first b.... 'The Maldives has also asked us to recruit...
...d? Yes, within the brain, say researchers. Brain ...essing mechanism has never been easy. //Meditators...ntly chattering. Researchers have come up with a f...n you least expect it. We often experience that th...
...ual health campaign is targeting young adults to c...r focus is mainly on 18 to 24-year-olds. //Current...ed to carry condoms on a night out. The ?4m ca...ealth groups but pointed out that a further ?46m h...
...captured the imagination of the world as a 'repeto...joled into restoring or rejuvenating debilitating ...ientists have helped to reiterate this belief, by ... could be lauded as a 'mile stone' in stem cell re...
...opular world over for its quality poultry products...ed to a record 3.26 Billion Rupees. //However the ...rldwide epidemic brought the poultry revenues cras...Influenza' has been known to affect humans though ...
Other Medicine News:Health News:Picture Book Reading Helps Toddlers Grasp Complex Actions 2Health News:Noise In Neurons Is good 2Health News:Risk-Taking Young Urged To Carry Condoms 2Health News:Research 'Extraordinaire' To Restore Vision 2Health News:India Free From Bird Flu 2
(Date:12/1/2009)...., Dec. 1 CeloNova BioSciences, In... medical devices and of specialty implants, today ..., founder and medical director of Baptist Cardiac ...iscuss the CATANIA(TM) Stent System with NanoThin ...lar Interventions Conference to be held at the Hot...
(Date:12/1/2009)... and TOKYO, Dec. 1 Galenea Corp. a... the further extension of their research and devel...tension increases the collaboration term to seven ...proximately $90 million. The companies have been ...of discovering and developing first-in-class thera...
(Date:12/1/2009)...., Dec. 1 SCOLR Pharma, ... 20, 2009 it licensed to Chrono Nutraceuticals LLC...l four extended release dietary supplements using ...rm. In addition, SCOLR granted Chrono rights to m...ited States on a nonexclusive basis. Chrono paid ...
Breaking Medicine Technology:Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3American Nurses Association Joins the National Healthcare Career Network 54285 1American Nurses Association Joins the National Healthcare Career Network 54285 2American Nurses Association Joins the National Healthcare Career Network 54285 3Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 1Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 2Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 3The tourist trap 9540 1
...ial New Front-Line Treatment ...Genzyme Corp.,(Nasdaq: GENZ ) reported preliminar...2 study examining the safety and effectiveness of ...ously untreated, older adult,patients with acute m...fit,from conventional "7+3" anthracycline plus cyt...
...CALS, INC. (Nasdaq: VION ) today announced that i... lead anticancer agent Cloretazine(R),(VNP40101M) ...yelogenous,leukemia (AML) had been presented at th...linical Oncology (ASCO(R)) in Chicago, Illinois., ...atients. The median,age of these patients was 73 y...
Other Medicine Technology:Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4
Fast-Cath™ Guiding Introducers
Lumenis 1000 Integrated Slit Lamp
Novus 30001
Selecta Trio Photocoagulator and SLT Combination Laser
Medicine Products: